Analytical Data
-
Gene name
metB
- Application
-
Alternative Names
metB; Staphylococcus aureus (strain Newman)
-
Species
Others
-
Source
E. coli
-
Tag
Strep;His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A0H3K724
-
Expression Region
N2-L380
-
Protein Length
Full Length of Mature Protein
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of IGKC (Immunoglobulin kappa chain) recombinant proteins is driven by the need to better understand the immune system's functioning and the role of antibodies in various diseases. Immunoglobulin kappa light chains are crucial components of antibodies, playing a vital role in antigen recognition and immune response. Research into IGKC recombinant proteins enables scientists to explore their structural and functional characteristics, which is essential for developing therapeutic antibodies and diagnostic tools. In addition, the use of recombinant technology allows for the production of large quantities of IGKC, facilitating studies on its interactions with other immunological components and its implications in conditions such as autoimmune diseases, cancers, and infections. Furthermore, understanding the variations in IGKC expression across different populations can provide insights into individual susceptibility to diseases and inform personalized medicine approaches. The advancements in biotechnological methods for producing and characterizing these proteins are thus crucial for enhancing our therapeutic strategies and improving health outcomes.
